PDCD1 and non-small cell lung carcinoma: Recently, immunotherapy with immune checkpoint inhibitors (ICIs) such as programmed cell death-1 (PD-1)- and programmed death-ligand 1 (PD-L1) monoclonal antibodies (mAbs) has revolutionized the treatment algorithm of several types of cancer including NSCLC [16–23].